转化医学杂志2024，Vol.13Issue(11)：2011-2014,4.DOI:10.3639/j.issn.2095-3097.2024.11.047
达格列净联合标准化药物治疗对顽固性心力衰竭合并起搏器植入患者的疗效及安全性分析
Analysis of the Efficacy and Safety of Dapagliflozin Combined with Standardized Drug Therapy in Patients with Refractory Heart Failure and Pacemaker Implantation
摘要
Abstract
Objective To analyze the efficacy and safety of dapagliflozin combined with standardized drug therapy in patients with refractory heart failure and pacemaker implantation.Methods A retrospective study was conducted on 102 pa-tients with refractory heart failure and pacemaker implantation admitted to Xi'an Gaoxin Hospital in Shaanxi Province from May 2022 to May 2024.Patients were divided into a conventional group(standardized drug therapy,n=46)and a combination group(dapagliflozin added to standardized drug therapy,n=56).The clinical efficacy,cardiac function[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),and left ventricular posterior wall thickness(LVPWD)],inflammatory factors[tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),and high-sensitivity C-reactive protein(hs-CRP)],and ad-verse reactions were compared between the two groups.Results The total effective rate was higher in the combination group than in the conventional group.After treatment,LVEF was higher,while LVEDD,LVPWD,TNF-α,IL-6,and hs-CRP were lower in the combination group,with statistically significant differences between the groups(all P<0.05).There was no signifi-cant difference in adverse reactions between the two groups(P>0.05).Conclusion Dapagliflozin combined with standardized drug therapy has ideal efficacy in the treatment of refractory heart failure with pacemaker implantation,improving cardiac func-tion,regulating the expression of inflammatory factors,and demonstrating high safety.关键词
达格列净/标准化药物治疗/顽固性心力衰竭/起搏器植入Key words
Dapagliflozin/Standardized drug therapy/Refractory heart failure/Pacemaker implantation分类
医药卫生引用本文复制引用
韩震海,闫妮,惠玲玲..达格列净联合标准化药物治疗对顽固性心力衰竭合并起搏器植入患者的疗效及安全性分析[J].转化医学杂志,2024,13(11):2011-2014,4.基金项目
国家自然科学基金(82100830) （82100830）
